nodes	percent_of_prediction	percent_of_DWPC	metapath
Sibutramine—SLC6A3—malignant glioma	0.744	1	CbGaD
Sibutramine—CYP3A4—Temozolomide—malignant glioma	0.0799	1	CbGbCtD
Sibutramine—Brain neoplasm—Carmustine—malignant glioma	0.0117	0.0756	CcSEcCtD
Sibutramine—SLC6A3—telencephalic ventricle—malignant glioma	0.00352	0.246	CbGeAlD
Sibutramine—Facial paralysis—Carmustine—malignant glioma	0.00346	0.0224	CcSEcCtD
Sibutramine—VIIth nerve paralysis—Carmustine—malignant glioma	0.00268	0.0174	CcSEcCtD
Sibutramine—Personality disorder—Carmustine—malignant glioma	0.00254	0.0165	CcSEcCtD
Sibutramine—Cerebral ischaemia—Temozolomide—malignant glioma	0.0022	0.0142	CcSEcCtD
Sibutramine—Transient ischaemic attack—Temozolomide—malignant glioma	0.00211	0.0136	CcSEcCtD
Sibutramine—Haemorrhoids—Temozolomide—malignant glioma	0.00181	0.0117	CcSEcCtD
Sibutramine—Cerebration impaired—Temozolomide—malignant glioma	0.00181	0.0117	CcSEcCtD
Sibutramine—Myasthenia—Carmustine—malignant glioma	0.00175	0.0113	CcSEcCtD
Sibutramine—Parosmia—Temozolomide—malignant glioma	0.00164	0.0106	CcSEcCtD
Sibutramine—Tooth disorder—Temozolomide—malignant glioma	0.00164	0.0106	CcSEcCtD
Sibutramine—Myopathy—Temozolomide—malignant glioma	0.00152	0.00982	CcSEcCtD
Sibutramine—Lung disorder—Temozolomide—malignant glioma	0.0015	0.00973	CcSEcCtD
Sibutramine—Apathy—Temozolomide—malignant glioma	0.00149	0.00964	CcSEcCtD
Sibutramine—Flat affect—Temozolomide—malignant glioma	0.00147	0.00955	CcSEcCtD
Sibutramine—Vaginal haemorrhage—Temozolomide—malignant glioma	0.00144	0.0093	CcSEcCtD
Sibutramine—Herpes zoster—Temozolomide—malignant glioma	0.00141	0.00914	CcSEcCtD
Sibutramine—Abscess—Carmustine—malignant glioma	0.00139	0.009	CcSEcCtD
Sibutramine—Otitis media—Temozolomide—malignant glioma	0.00137	0.00884	CcSEcCtD
Sibutramine—Petechiae—Temozolomide—malignant glioma	0.00129	0.00837	CcSEcCtD
Sibutramine—Gamma-glutamyltransferase increased—Temozolomide—malignant glioma	0.00129	0.00837	CcSEcCtD
Sibutramine—Speech disorder—Carmustine—malignant glioma	0.00128	0.00828	CcSEcCtD
Sibutramine—Accidental injury—Carmustine—malignant glioma	0.00124	0.00805	CcSEcCtD
Sibutramine—Speech disorder—Temozolomide—malignant glioma	0.00124	0.008	CcSEcCtD
Sibutramine—Disturbance in attention—Temozolomide—malignant glioma	0.00123	0.00795	CcSEcCtD
Sibutramine—Amenorrhoea—Temozolomide—malignant glioma	0.00121	0.00783	CcSEcCtD
Sibutramine—Thinking abnormal—Carmustine—malignant glioma	0.0012	0.00778	CcSEcCtD
Sibutramine—Leukocytosis—Carmustine—malignant glioma	0.00117	0.00758	CcSEcCtD
Sibutramine—Hyperbilirubinaemia—Temozolomide—malignant glioma	0.00117	0.00757	CcSEcCtD
Sibutramine—Herpes simplex—Temozolomide—malignant glioma	0.00115	0.00747	CcSEcCtD
Sibutramine—Gait disturbance—Carmustine—malignant glioma	0.00113	0.0073	CcSEcCtD
Sibutramine—Neck pain—Carmustine—malignant glioma	0.00111	0.00721	CcSEcCtD
Sibutramine—Gait disturbance—Temozolomide—malignant glioma	0.00109	0.00705	CcSEcCtD
Sibutramine—Phosphatase alkaline increased—Temozolomide—malignant glioma	0.00106	0.00688	CcSEcCtD
Sibutramine—Urinary incontinence—Carmustine—malignant glioma	0.00106	0.00688	CcSEcCtD
Sibutramine—Urinary incontinence—Temozolomide—malignant glioma	0.00103	0.00665	CcSEcCtD
Sibutramine—Neoplasm—Carmustine—malignant glioma	0.000995	0.00644	CcSEcCtD
Sibutramine—Dry eye—Temozolomide—malignant glioma	0.000982	0.00636	CcSEcCtD
Sibutramine—Neoplasm—Temozolomide—malignant glioma	0.000961	0.00622	CcSEcCtD
Sibutramine—Abnormal vision—Carmustine—malignant glioma	0.000959	0.00621	CcSEcCtD
Sibutramine—Sepsis—Carmustine—malignant glioma	0.000955	0.00618	CcSEcCtD
Sibutramine—Mental disability—Carmustine—malignant glioma	0.000955	0.00618	CcSEcCtD
Sibutramine—SLC6A3—brainstem—malignant glioma	0.000951	0.0667	CbGeAlD
Sibutramine—Abnormal vision—Temozolomide—malignant glioma	0.000927	0.006	CcSEcCtD
Sibutramine—Phlebitis—Carmustine—malignant glioma	0.000927	0.006	CcSEcCtD
Sibutramine—Mental disability—Temozolomide—malignant glioma	0.000922	0.00597	CcSEcCtD
Sibutramine—Diabetes mellitus—Carmustine—malignant glioma	0.000918	0.00595	CcSEcCtD
Sibutramine—Ear pain—Temozolomide—malignant glioma	0.000904	0.00586	CcSEcCtD
Sibutramine—Blood alkaline phosphatase increased—Temozolomide—malignant glioma	0.000887	0.00575	CcSEcCtD
Sibutramine—Eye pain—Carmustine—malignant glioma	0.000884	0.00573	CcSEcCtD
Sibutramine—SLC6A4—brainstem—malignant glioma	0.000872	0.0611	CbGeAlD
Sibutramine—Gastroenteritis—Temozolomide—malignant glioma	0.000871	0.00564	CcSEcCtD
Sibutramine—Injury—Carmustine—malignant glioma	0.000869	0.00563	CcSEcCtD
Sibutramine—Vascular purpura—Temozolomide—malignant glioma	0.000863	0.00559	CcSEcCtD
Sibutramine—Eye pain—Temozolomide—malignant glioma	0.000855	0.00554	CcSEcCtD
Sibutramine—Amnesia—Carmustine—malignant glioma	0.00085	0.0055	CcSEcCtD
Sibutramine—Nasal congestion—Temozolomide—malignant glioma	0.000847	0.00549	CcSEcCtD
Sibutramine—SLC6A3—telencephalon—malignant glioma	0.000844	0.0592	CbGeAlD
Sibutramine—Amnesia—Temozolomide—malignant glioma	0.000821	0.00532	CcSEcCtD
Sibutramine—Thirst—Temozolomide—malignant glioma	0.000811	0.00525	CcSEcCtD
Sibutramine—Purpura—Temozolomide—malignant glioma	0.000801	0.00518	CcSEcCtD
Sibutramine—Gastrointestinal haemorrhage—Carmustine—malignant glioma	0.000798	0.00517	CcSEcCtD
Sibutramine—SLC6A4—telencephalon—malignant glioma	0.000774	0.0542	CbGeAlD
Sibutramine—Face oedema—Carmustine—malignant glioma	0.000771	0.00499	CcSEcCtD
Sibutramine—SLC6A2—brainstem—malignant glioma	0.000768	0.0538	CbGeAlD
Sibutramine—Affect lability—Temozolomide—malignant glioma	0.00076	0.00492	CcSEcCtD
Sibutramine—Ataxia—Carmustine—malignant glioma	0.000751	0.00486	CcSEcCtD
Sibutramine—Face oedema—Temozolomide—malignant glioma	0.000745	0.00482	CcSEcCtD
Sibutramine—Liver function test abnormal—Carmustine—malignant glioma	0.000737	0.00477	CcSEcCtD
Sibutramine—Mood swings—Temozolomide—malignant glioma	0.000731	0.00473	CcSEcCtD
Sibutramine—Hypokalaemia—Carmustine—malignant glioma	0.000727	0.00471	CcSEcCtD
Sibutramine—Ataxia—Temozolomide—malignant glioma	0.000726	0.0047	CcSEcCtD
Sibutramine—Dehydration—Temozolomide—malignant glioma	0.000718	0.00465	CcSEcCtD
Sibutramine—Dry skin—Temozolomide—malignant glioma	0.000707	0.00458	CcSEcCtD
Sibutramine—Muscular weakness—Carmustine—malignant glioma	0.000704	0.00456	CcSEcCtD
Sibutramine—Hypokalaemia—Temozolomide—malignant glioma	0.000702	0.00455	CcSEcCtD
Sibutramine—Aspartate aminotransferase increased—Temozolomide—malignant glioma	0.000695	0.0045	CcSEcCtD
Sibutramine—Dysphagia—Carmustine—malignant glioma	0.00069	0.00447	CcSEcCtD
Sibutramine—SLC6A2—telencephalon—malignant glioma	0.000681	0.0477	CbGeAlD
Sibutramine—Muscular weakness—Temozolomide—malignant glioma	0.000681	0.00441	CcSEcCtD
Sibutramine—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.000681	0.00441	CcSEcCtD
Sibutramine—Abdominal distension—Temozolomide—malignant glioma	0.000671	0.00435	CcSEcCtD
Sibutramine—Dysphagia—Temozolomide—malignant glioma	0.000667	0.00432	CcSEcCtD
Sibutramine—Bronchitis—Temozolomide—malignant glioma	0.000641	0.00415	CcSEcCtD
Sibutramine—Dysuria—Temozolomide—malignant glioma	0.000624	0.00404	CcSEcCtD
Sibutramine—Hyperglycaemia—Carmustine—malignant glioma	0.000623	0.00403	CcSEcCtD
Sibutramine—Pneumonia—Carmustine—malignant glioma	0.000619	0.00401	CcSEcCtD
Sibutramine—Pollakiuria—Temozolomide—malignant glioma	0.000616	0.00399	CcSEcCtD
Sibutramine—Erectile dysfunction—Temozolomide—malignant glioma	0.000614	0.00398	CcSEcCtD
Sibutramine—Depression—Carmustine—malignant glioma	0.000614	0.00397	CcSEcCtD
Sibutramine—Photosensitivity reaction—Temozolomide—malignant glioma	0.000609	0.00394	CcSEcCtD
Sibutramine—Weight increased—Temozolomide—malignant glioma	0.000607	0.00393	CcSEcCtD
Sibutramine—SLC6A3—midbrain—malignant glioma	0.000606	0.0425	CbGeAlD
Sibutramine—Renal failure—Carmustine—malignant glioma	0.000605	0.00392	CcSEcCtD
Sibutramine—Neuropathy peripheral—Carmustine—malignant glioma	0.000603	0.00391	CcSEcCtD
Sibutramine—Hyperglycaemia—Temozolomide—malignant glioma	0.000602	0.0039	CcSEcCtD
Sibutramine—Stomatitis—Carmustine—malignant glioma	0.0006	0.00388	CcSEcCtD
Sibutramine—Urinary tract infection—Carmustine—malignant glioma	0.000598	0.00387	CcSEcCtD
Sibutramine—Pneumonia—Temozolomide—malignant glioma	0.000598	0.00387	CcSEcCtD
Sibutramine—Depression—Temozolomide—malignant glioma	0.000593	0.00384	CcSEcCtD
Sibutramine—SLC6A3—spinal cord—malignant glioma	0.000592	0.0415	CbGeAlD
Sibutramine—Neuropathy peripheral—Temozolomide—malignant glioma	0.000583	0.00377	CcSEcCtD
Sibutramine—Stomatitis—Temozolomide—malignant glioma	0.00058	0.00375	CcSEcCtD
Sibutramine—Urinary tract infection—Temozolomide—malignant glioma	0.000578	0.00374	CcSEcCtD
Sibutramine—Sinusitis—Temozolomide—malignant glioma	0.000558	0.00361	CcSEcCtD
Sibutramine—SLC6A4—midbrain—malignant glioma	0.000556	0.0389	CbGeAlD
Sibutramine—Haemoglobin—Carmustine—malignant glioma	0.000555	0.0036	CcSEcCtD
Sibutramine—Haemorrhage—Carmustine—malignant glioma	0.000552	0.00358	CcSEcCtD
Sibutramine—Hypoaesthesia—Carmustine—malignant glioma	0.00055	0.00356	CcSEcCtD
Sibutramine—Oedema peripheral—Carmustine—malignant glioma	0.000544	0.00352	CcSEcCtD
Sibutramine—SLC6A4—spinal cord—malignant glioma	0.000542	0.038	CbGeAlD
Sibutramine—Haemoglobin—Temozolomide—malignant glioma	0.000537	0.00347	CcSEcCtD
Sibutramine—SLC6A2—medulla oblongata—malignant glioma	0.000535	0.0375	CbGeAlD
Sibutramine—Haemorrhage—Temozolomide—malignant glioma	0.000534	0.00346	CcSEcCtD
Sibutramine—Visual impairment—Carmustine—malignant glioma	0.000532	0.00345	CcSEcCtD
Sibutramine—Hypoaesthesia—Temozolomide—malignant glioma	0.000531	0.00344	CcSEcCtD
Sibutramine—Pharyngitis—Temozolomide—malignant glioma	0.00053	0.00343	CcSEcCtD
Sibutramine—Oedema peripheral—Temozolomide—malignant glioma	0.000526	0.00341	CcSEcCtD
Sibutramine—Eye disorder—Carmustine—malignant glioma	0.000516	0.00334	CcSEcCtD
Sibutramine—Visual impairment—Temozolomide—malignant glioma	0.000514	0.00333	CcSEcCtD
Sibutramine—Eye disorder—Temozolomide—malignant glioma	0.000499	0.00323	CcSEcCtD
Sibutramine—Tinnitus—Temozolomide—malignant glioma	0.000498	0.00322	CcSEcCtD
Sibutramine—Arrhythmia—Carmustine—malignant glioma	0.000493	0.0032	CcSEcCtD
Sibutramine—Alopecia—Carmustine—malignant glioma	0.000488	0.00316	CcSEcCtD
Sibutramine—Angiopathy—Temozolomide—malignant glioma	0.000484	0.00314	CcSEcCtD
Sibutramine—Immune system disorder—Temozolomide—malignant glioma	0.000482	0.00312	CcSEcCtD
Sibutramine—Malnutrition—Carmustine—malignant glioma	0.000481	0.00311	CcSEcCtD
Sibutramine—SLC6A3—central nervous system—malignant glioma	0.00048	0.0336	CbGeAlD
Sibutramine—Chills—Temozolomide—malignant glioma	0.000479	0.0031	CcSEcCtD
Sibutramine—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—BCHE—malignant glioma	0.000475	0.066	CbGpPWpGaD
Sibutramine—Alopecia—Temozolomide—malignant glioma	0.000472	0.00305	CcSEcCtD
Sibutramine—SLC6A3—cerebellum—malignant glioma	0.000469	0.0329	CbGeAlD
Sibutramine—Back pain—Carmustine—malignant glioma	0.000465	0.00301	CcSEcCtD
Sibutramine—Malnutrition—Temozolomide—malignant glioma	0.000465	0.00301	CcSEcCtD
Sibutramine—Dysgeusia—Temozolomide—malignant glioma	0.000455	0.00295	CcSEcCtD
Sibutramine—Vision blurred—Carmustine—malignant glioma	0.000453	0.00293	CcSEcCtD
Sibutramine—Tremor—Carmustine—malignant glioma	0.000451	0.00292	CcSEcCtD
Sibutramine—Back pain—Temozolomide—malignant glioma	0.000449	0.00291	CcSEcCtD
Sibutramine—Anaemia—Carmustine—malignant glioma	0.000444	0.00288	CcSEcCtD
Sibutramine—Agitation—Carmustine—malignant glioma	0.000442	0.00286	CcSEcCtD
Sibutramine—SLC6A4—central nervous system—malignant glioma	0.00044	0.0308	CbGeAlD
Sibutramine—Vision blurred—Temozolomide—malignant glioma	0.000438	0.00284	CcSEcCtD
Sibutramine—Tremor—Temozolomide—malignant glioma	0.000435	0.00282	CcSEcCtD
Sibutramine—Ill-defined disorder—Temozolomide—malignant glioma	0.000431	0.00279	CcSEcCtD
Sibutramine—Leukopenia—Carmustine—malignant glioma	0.00043	0.00279	CcSEcCtD
Sibutramine—SLC6A4—Synaptic Vesicle Pathway—SYP—malignant glioma	0.00043	0.0596	CbGpPWpGaD
Sibutramine—Anaemia—Temozolomide—malignant glioma	0.000429	0.00278	CcSEcCtD
Sibutramine—Agitation—Temozolomide—malignant glioma	0.000427	0.00277	CcSEcCtD
Sibutramine—Angioedema—Temozolomide—malignant glioma	0.000425	0.00275	CcSEcCtD
Sibutramine—Malaise—Temozolomide—malignant glioma	0.000419	0.00271	CcSEcCtD
Sibutramine—Vertigo—Temozolomide—malignant glioma	0.000417	0.0027	CcSEcCtD
Sibutramine—Convulsion—Carmustine—malignant glioma	0.000417	0.0027	CcSEcCtD
Sibutramine—Leukopenia—Temozolomide—malignant glioma	0.000416	0.00269	CcSEcCtD
Sibutramine—Hypertension—Carmustine—malignant glioma	0.000415	0.00269	CcSEcCtD
Sibutramine—Palpitations—Temozolomide—malignant glioma	0.000411	0.00266	CcSEcCtD
Sibutramine—Myalgia—Carmustine—malignant glioma	0.000409	0.00265	CcSEcCtD
Sibutramine—Chest pain—Carmustine—malignant glioma	0.000409	0.00265	CcSEcCtD
Sibutramine—Anxiety—Carmustine—malignant glioma	0.000408	0.00264	CcSEcCtD
Sibutramine—Cough—Temozolomide—malignant glioma	0.000405	0.00263	CcSEcCtD
Sibutramine—Convulsion—Temozolomide—malignant glioma	0.000403	0.00261	CcSEcCtD
Sibutramine—Hypertension—Temozolomide—malignant glioma	0.000401	0.0026	CcSEcCtD
Sibutramine—Confusional state—Carmustine—malignant glioma	0.000396	0.00256	CcSEcCtD
Sibutramine—Myalgia—Temozolomide—malignant glioma	0.000396	0.00256	CcSEcCtD
Sibutramine—Arthralgia—Temozolomide—malignant glioma	0.000396	0.00256	CcSEcCtD
Sibutramine—Anxiety—Temozolomide—malignant glioma	0.000394	0.00255	CcSEcCtD
Sibutramine—Oedema—Carmustine—malignant glioma	0.000392	0.00254	CcSEcCtD
Sibutramine—Discomfort—Temozolomide—malignant glioma	0.000391	0.00253	CcSEcCtD
Sibutramine—Infection—Carmustine—malignant glioma	0.00039	0.00252	CcSEcCtD
Sibutramine—SLC6A2—central nervous system—malignant glioma	0.000387	0.0271	CbGeAlD
Sibutramine—Dry mouth—Temozolomide—malignant glioma	0.000387	0.00251	CcSEcCtD
Sibutramine—Thrombocytopenia—Carmustine—malignant glioma	0.000384	0.00249	CcSEcCtD
Sibutramine—Tachycardia—Carmustine—malignant glioma	0.000383	0.00248	CcSEcCtD
Sibutramine—Confusional state—Temozolomide—malignant glioma	0.000382	0.00248	CcSEcCtD
Sibutramine—SLC6A3—brain—malignant glioma	0.000381	0.0267	CbGeAlD
Sibutramine—Anaphylactic shock—Temozolomide—malignant glioma	0.000379	0.00246	CcSEcCtD
Sibutramine—Oedema—Temozolomide—malignant glioma	0.000379	0.00246	CcSEcCtD
Sibutramine—Infection—Temozolomide—malignant glioma	0.000377	0.00244	CcSEcCtD
Sibutramine—Anorexia—Carmustine—malignant glioma	0.000374	0.00242	CcSEcCtD
Sibutramine—Thrombocytopenia—Temozolomide—malignant glioma	0.000371	0.0024	CcSEcCtD
Sibutramine—Skin disorder—Temozolomide—malignant glioma	0.000368	0.00239	CcSEcCtD
Sibutramine—Hypotension—Carmustine—malignant glioma	0.000367	0.00237	CcSEcCtD
Sibutramine—Hyperhidrosis—Temozolomide—malignant glioma	0.000367	0.00237	CcSEcCtD
Sibutramine—Anorexia—Temozolomide—malignant glioma	0.000362	0.00234	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Carmustine—malignant glioma	0.000358	0.00232	CcSEcCtD
Sibutramine—Insomnia—Carmustine—malignant glioma	0.000355	0.0023	CcSEcCtD
Sibutramine—Paraesthesia—Carmustine—malignant glioma	0.000352	0.00228	CcSEcCtD
Sibutramine—Dyspnoea—Carmustine—malignant glioma	0.00035	0.00227	CcSEcCtD
Sibutramine—SLC6A4—brain—malignant glioma	0.000349	0.0245	CbGeAlD
Sibutramine—Somnolence—Carmustine—malignant glioma	0.000349	0.00226	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000346	0.00224	CcSEcCtD
Sibutramine—Insomnia—Temozolomide—malignant glioma	0.000343	0.00222	CcSEcCtD
Sibutramine—Decreased appetite—Carmustine—malignant glioma	0.000341	0.00221	CcSEcCtD
Sibutramine—Paraesthesia—Temozolomide—malignant glioma	0.000341	0.00221	CcSEcCtD
Sibutramine—Gastrointestinal disorder—Carmustine—malignant glioma	0.000339	0.00219	CcSEcCtD
Sibutramine—Dyspnoea—Temozolomide—malignant glioma	0.000338	0.00219	CcSEcCtD
Sibutramine—Somnolence—Temozolomide—malignant glioma	0.000337	0.00218	CcSEcCtD
Sibutramine—Pain—Carmustine—malignant glioma	0.000336	0.00217	CcSEcCtD
Sibutramine—Constipation—Carmustine—malignant glioma	0.000336	0.00217	CcSEcCtD
Sibutramine—Dyspepsia—Temozolomide—malignant glioma	0.000334	0.00216	CcSEcCtD
Sibutramine—Decreased appetite—Temozolomide—malignant glioma	0.00033	0.00214	CcSEcCtD
Sibutramine—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000327	0.00212	CcSEcCtD
Sibutramine—Pain—Temozolomide—malignant glioma	0.000324	0.0021	CcSEcCtD
Sibutramine—Constipation—Temozolomide—malignant glioma	0.000324	0.0021	CcSEcCtD
Sibutramine—Feeling abnormal—Carmustine—malignant glioma	0.000323	0.00209	CcSEcCtD
Sibutramine—Gastrointestinal pain—Carmustine—malignant glioma	0.000321	0.00208	CcSEcCtD
Sibutramine—Feeling abnormal—Temozolomide—malignant glioma	0.000313	0.00202	CcSEcCtD
Sibutramine—Abdominal pain—Carmustine—malignant glioma	0.00031	0.00201	CcSEcCtD
Sibutramine—Body temperature increased—Carmustine—malignant glioma	0.00031	0.00201	CcSEcCtD
Sibutramine—Gastrointestinal pain—Temozolomide—malignant glioma	0.00031	0.00201	CcSEcCtD
Sibutramine—SLC6A2—brain—malignant glioma	0.000307	0.0215	CbGeAlD
Sibutramine—Urticaria—Temozolomide—malignant glioma	0.000301	0.00195	CcSEcCtD
Sibutramine—Body temperature increased—Temozolomide—malignant glioma	0.0003	0.00194	CcSEcCtD
Sibutramine—Abdominal pain—Temozolomide—malignant glioma	0.0003	0.00194	CcSEcCtD
Sibutramine—Hypersensitivity—Carmustine—malignant glioma	0.000289	0.00187	CcSEcCtD
Sibutramine—Asthenia—Carmustine—malignant glioma	0.000282	0.00182	CcSEcCtD
Sibutramine—Hypersensitivity—Temozolomide—malignant glioma	0.000279	0.00181	CcSEcCtD
Sibutramine—Asthenia—Temozolomide—malignant glioma	0.000272	0.00176	CcSEcCtD
Sibutramine—Diarrhoea—Carmustine—malignant glioma	0.000269	0.00174	CcSEcCtD
Sibutramine—Pruritus—Temozolomide—malignant glioma	0.000268	0.00174	CcSEcCtD
Sibutramine—Dizziness—Carmustine—malignant glioma	0.00026	0.00168	CcSEcCtD
Sibutramine—Diarrhoea—Temozolomide—malignant glioma	0.000259	0.00168	CcSEcCtD
Sibutramine—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—malignant glioma	0.000253	0.0351	CbGpPWpGaD
Sibutramine—Dizziness—Temozolomide—malignant glioma	0.000251	0.00162	CcSEcCtD
Sibutramine—Vomiting—Carmustine—malignant glioma	0.00025	0.00162	CcSEcCtD
Sibutramine—Rash—Carmustine—malignant glioma	0.000247	0.0016	CcSEcCtD
Sibutramine—Dermatitis—Carmustine—malignant glioma	0.000247	0.0016	CcSEcCtD
Sibutramine—Headache—Carmustine—malignant glioma	0.000246	0.00159	CcSEcCtD
Sibutramine—Vomiting—Temozolomide—malignant glioma	0.000241	0.00156	CcSEcCtD
Sibutramine—Rash—Temozolomide—malignant glioma	0.000239	0.00155	CcSEcCtD
Sibutramine—Dermatitis—Temozolomide—malignant glioma	0.000239	0.00155	CcSEcCtD
Sibutramine—Headache—Temozolomide—malignant glioma	0.000238	0.00154	CcSEcCtD
Sibutramine—Nausea—Carmustine—malignant glioma	0.000233	0.00151	CcSEcCtD
Sibutramine—Nausea—Temozolomide—malignant glioma	0.000225	0.00146	CcSEcCtD
Sibutramine—SLC6A3—Dopaminergic Neurogenesis—SOX2—malignant glioma	0.000218	0.0302	CbGpPWpGaD
Sibutramine—CYP3A4—central nervous system—malignant glioma	0.000215	0.0151	CbGeAlD
Sibutramine—SLC6A3—Alpha-synuclein signaling—PARK2—malignant glioma	0.000211	0.0292	CbGpPWpGaD
Sibutramine—CYP3A4—Liver X Receptor Pathway—CYP2B6—malignant glioma	0.000199	0.0277	CbGpPWpGaD
Sibutramine—SLC6A4—Monoamine Transport—SLC6A3—malignant glioma	0.000194	0.0269	CbGpPWpGaD
Sibutramine—SLC6A4—Serotonin Transporter Activity—IL1B—malignant glioma	0.000186	0.0257	CbGpPWpGaD
Sibutramine—SLC6A3—Parkinsons Disease Pathway—PARK2—malignant glioma	0.000179	0.0248	CbGpPWpGaD
Sibutramine—SLC6A2—Amine compound SLC transporters—SLC6A3—malignant glioma	0.000175	0.0243	CbGpPWpGaD
Sibutramine—SLC6A2—Monoamine Transport—SLC6A3—malignant glioma	0.000166	0.0231	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—FTH1—malignant glioma	0.000151	0.021	CbGpPWpGaD
Sibutramine—CYP3A4—Oxidation by Cytochrome P450—POR—malignant glioma	0.000135	0.0187	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—FTH1—malignant glioma	0.00013	0.018	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—FTH1—malignant glioma	0.000115	0.016	CbGpPWpGaD
Sibutramine—CYP3A4—Xenobiotics—CYP2B6—malignant glioma	0.000115	0.0159	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—NTRK3—malignant glioma	0.000109	0.0151	CbGpPWpGaD
Sibutramine—CYP3A4—Xenobiotics—CYP2C18—malignant glioma	9.93e-05	0.0138	CbGpPWpGaD
Sibutramine—CYP3A4—Irinotecan Pathway—BCHE—malignant glioma	9.31e-05	0.0129	CbGpPWpGaD
Sibutramine—SLC6A3—Alpha-synuclein signaling—BAD—malignant glioma	9.02e-05	0.0125	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—RUNX3—malignant glioma	8.58e-05	0.0119	CbGpPWpGaD
Sibutramine—CYP3A4—Tryptophan metabolism—ASMT—malignant glioma	8.26e-05	0.0115	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—MYB—malignant glioma	7.92e-05	0.011	CbGpPWpGaD
Sibutramine—SLC6A4—Monoamine Transport—IL1B—malignant glioma	7.9e-05	0.011	CbGpPWpGaD
Sibutramine—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2B6—malignant glioma	7.86e-05	0.0109	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—SOX2—malignant glioma	7.65e-05	0.0106	CbGpPWpGaD
Sibutramine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2B6—malignant glioma	7.49e-05	0.0104	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—APOD—malignant glioma	6.96e-05	0.00966	CbGpPWpGaD
Sibutramine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—malignant glioma	6.86e-05	0.00951	CbGpPWpGaD
Sibutramine—SLC6A2—Monoamine Transport—IL1B—malignant glioma	6.79e-05	0.00942	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—APOD—malignant glioma	6.17e-05	0.00856	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—SLC5A5—malignant glioma	6.04e-05	0.00838	CbGpPWpGaD
Sibutramine—SLC6A3—Monoamine Transport—IL1B—malignant glioma	6.02e-05	0.00835	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—YWHAE—malignant glioma	5.95e-05	0.00826	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—NTRK2—malignant glioma	5.95e-05	0.00826	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—SLC6A3—malignant glioma	5.75e-05	0.00798	CbGpPWpGaD
Sibutramine—SLC6A4—Monoamine Transport—TNF—malignant glioma	5.73e-05	0.00795	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—PML—malignant glioma	5.57e-05	0.00772	CbGpPWpGaD
Sibutramine—SLC6A3—Dopaminergic Neurogenesis—STAT3—malignant glioma	5.31e-05	0.00737	CbGpPWpGaD
Sibutramine—SLC6A3—Parkinsons Disease Pathway—CASP3—malignant glioma	5.23e-05	0.00726	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—SLC5A5—malignant glioma	5.19e-05	0.00721	CbGpPWpGaD
Sibutramine—CYP3A4—Tryptophan metabolism—CYP2C18—malignant glioma	5.1e-05	0.00708	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—TOP2A—malignant glioma	5.09e-05	0.00707	CbGpPWpGaD
Sibutramine—CYP3A4—Irinotecan Pathway—APC—malignant glioma	5.05e-05	0.00701	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—SLC6A3—malignant glioma	4.94e-05	0.00686	CbGpPWpGaD
Sibutramine—SLC6A2—Monoamine Transport—TNF—malignant glioma	4.93e-05	0.00684	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—GJA1—malignant glioma	4.89e-05	0.00678	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—GSTP1—malignant glioma	4.86e-05	0.00675	CbGpPWpGaD
Sibutramine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2B6—malignant glioma	4.76e-05	0.0066	CbGpPWpGaD
Sibutramine—CYP3A4—Oxidation by Cytochrome P450—CYP2B6—malignant glioma	4.69e-05	0.00651	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—SLC5A5—malignant glioma	4.6e-05	0.00638	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—COX8A—malignant glioma	4.55e-05	0.00631	CbGpPWpGaD
Sibutramine—SLC6A3—Monoamine Transport—TNF—malignant glioma	4.36e-05	0.00606	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—HES1—malignant glioma	4.26e-05	0.00592	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—GSTP1—malignant glioma	4.18e-05	0.0058	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—FTH1—malignant glioma	4.16e-05	0.00577	CbGpPWpGaD
Sibutramine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C18—malignant glioma	4.12e-05	0.00572	CbGpPWpGaD
Sibutramine—CYP3A4—Oxidation by Cytochrome P450—CYP2C18—malignant glioma	4.07e-05	0.00565	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—COX8A—malignant glioma	4.03e-05	0.00559	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—NTRK1—malignant glioma	3.96e-05	0.00549	CbGpPWpGaD
Sibutramine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2B6—malignant glioma	3.86e-05	0.00535	CbGpPWpGaD
Sibutramine—SLC6A4—NRF2 pathway—PDGFB—malignant glioma	3.85e-05	0.00534	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—GSTP1—malignant glioma	3.71e-05	0.00514	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—FTH1—malignant glioma	3.69e-05	0.00511	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—ATP1B2—malignant glioma	3.64e-05	0.00505	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—BCHE—malignant glioma	3.62e-05	0.00502	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—HIF1A—malignant glioma	3.57e-05	0.00496	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—APOD—malignant glioma	3.54e-05	0.00491	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—NCOR1—malignant glioma	3.46e-05	0.0048	CbGpPWpGaD
Sibutramine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C18—malignant glioma	3.34e-05	0.00464	CbGpPWpGaD
Sibutramine—SLC6A2—NRF2 pathway—PDGFB—malignant glioma	3.31e-05	0.00459	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—SLC5A5—malignant glioma	3.27e-05	0.00454	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—ATP1B2—malignant glioma	3.22e-05	0.00447	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—APOD—malignant glioma	3.13e-05	0.00435	CbGpPWpGaD
Sibutramine—SLC6A2—SLC-mediated transmembrane transport—SLC6A3—malignant glioma	3.12e-05	0.00432	CbGpPWpGaD
Sibutramine—SLC6A3—NRF2 pathway—PDGFB—malignant glioma	2.93e-05	0.00406	CbGpPWpGaD
Sibutramine—SLC6A3—SLC-mediated transmembrane transport—SLC5A5—malignant glioma	2.9e-05	0.00402	CbGpPWpGaD
Sibutramine—CYP3A4—Tryptophan metabolism—CAT—malignant glioma	2.78e-05	0.00386	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—BCHE—malignant glioma	2.77e-05	0.00385	CbGpPWpGaD
Sibutramine—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—malignant glioma	2.53e-05	0.00351	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—PPARG—malignant glioma	2.48e-05	0.00344	CbGpPWpGaD
Sibutramine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—malignant glioma	2.4e-05	0.00333	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—CXCL8—malignant glioma	2.32e-05	0.00322	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—IL1B—malignant glioma	2.22e-05	0.00309	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—CASP3—malignant glioma	2.22e-05	0.00308	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—CYP2B6—malignant glioma	2.05e-05	0.00284	CbGpPWpGaD
Sibutramine—CYP3A4—Metapathway biotransformation—CYP2B6—malignant glioma	2.02e-05	0.0028	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—malignant glioma	1.88e-05	0.00261	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—BRAF—malignant glioma	1.85e-05	0.00256	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—TFRC—malignant glioma	1.81e-05	0.00251	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—CYP2C18—malignant glioma	1.78e-05	0.00246	CbGpPWpGaD
Sibutramine—CYP3A4—Metapathway biotransformation—CYP2C18—malignant glioma	1.75e-05	0.00243	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—PTEN—malignant glioma	1.7e-05	0.00236	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC5A5—malignant glioma	1.66e-05	0.00231	CbGpPWpGaD
Sibutramine—SLC6A4—SIDS Susceptibility Pathways—TNF—malignant glioma	1.61e-05	0.00224	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—TFRC—malignant glioma	1.6e-05	0.00223	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—SLC6A3—malignant glioma	1.58e-05	0.0022	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—MDM2—malignant glioma	1.55e-05	0.00215	CbGpPWpGaD
Sibutramine—SLC6A3—Transmission across Chemical Synapses—RAF1—malignant glioma	1.54e-05	0.00214	CbGpPWpGaD
Sibutramine—CYP3A4—Tryptophan metabolism—MDM2—malignant glioma	1.54e-05	0.00213	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—SLC5A5—malignant glioma	1.47e-05	0.00204	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—GSTT1—malignant glioma	1.44e-05	0.00199	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—BRAF—malignant glioma	1.42e-05	0.00196	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—PTGS1—malignant glioma	1.35e-05	0.00187	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—MDM2—malignant glioma	1.19e-05	0.00165	CbGpPWpGaD
Sibutramine—SLC6A3—Neuronal System—RAF1—malignant glioma	1.18e-05	0.00164	CbGpPWpGaD
Sibutramine—SLC6A4—Circadian rythm related genes—TP53—malignant glioma	1.16e-05	0.00161	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—RTEL1—malignant glioma	1.01e-05	0.0014	CbGpPWpGaD
Sibutramine—CYP3A4—Biological oxidations—GSTP1—malignant glioma	9.95e-06	0.00138	CbGpPWpGaD
Sibutramine—CYP3A4—Metapathway biotransformation—GSTP1—malignant glioma	9.82e-06	0.00136	CbGpPWpGaD
Sibutramine—SLC6A2—Transmembrane transport of small molecules—RAF1—malignant glioma	7.17e-06	0.000995	CbGpPWpGaD
Sibutramine—SLC6A3—Transmembrane transport of small molecules—RAF1—malignant glioma	6.36e-06	0.000882	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—COX8A—malignant glioma	5.78e-06	0.000802	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—ASMT—malignant glioma	4.92e-06	0.000682	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—BCAN—malignant glioma	4.62e-06	0.000641	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—IDH2—malignant glioma	3.73e-06	0.000517	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CYP2B6—malignant glioma	3.5e-06	0.000486	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—IDH1—malignant glioma	3.2e-06	0.000444	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—SPHK1—malignant glioma	3.1e-06	0.00043	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CYP2C18—malignant glioma	3.04e-06	0.000421	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GSTT1—malignant glioma	2.46e-06	0.000341	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PTGS1—malignant glioma	2.3e-06	0.000319	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—BCHE—malignant glioma	2.14e-06	0.000297	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—SLC5A5—malignant glioma	2.11e-06	0.000293	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—GSTP1—malignant glioma	1.7e-06	0.000236	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CAT—malignant glioma	1.66e-06	0.00023	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—NCOR1—malignant glioma	1.56e-06	0.000217	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—CAV1—malignant glioma	1.28e-06	0.000177	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PIK3CG—malignant glioma	1.16e-06	0.000161	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PPARG—malignant glioma	1.12e-06	0.000156	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PIK3CD—malignant glioma	1.02e-06	0.000142	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PIK3CB—malignant glioma	8.9e-07	0.000123	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PTGS2—malignant glioma	8.82e-07	0.000122	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PTEN—malignant glioma	7.69e-07	0.000107	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—PIK3CA—malignant glioma	5.43e-07	7.53e-05	CbGpPWpGaD
Sibutramine—CYP3A4—Metabolism—AKT1—malignant glioma	4.43e-07	6.15e-05	CbGpPWpGaD
